---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-012846"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:36:19.328807+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology initiates combo trial PYX-201 + Keytruda and monotherapy expansion in HNSCC

## Summary
- Phase 1/2 combo trial PYX-201-102 with Keytruda (pembrolizumab) in multiple solid tumors including R/M HNSCC, HR+/HER2- BC, TNBC; first dosing on track for Q1 2025.
- Part 2 monotherapy expansion cohorts of Phase 1 PYX-201-101 began enrolling for 2L/3L R/M HNSCC patients who received prior platinum and PD-1 or EGFR and PD-1 inhibitors.
- PYX-201 is a first-in-concept ADC targeting Extradomain-B Fibronectin (EDB+FN) in tumor extracellular matrix, designed to induce immunogenic cell death.
- Combo trial is part of a Clinical Trial Collaboration Agreement with Merck (MRK).

## SEC filing metadata
- accession: 0000950170-25-012846
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017025012846/0000950170-25-012846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017025012846/pyxs-20250204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-012846
- JSON: https://secwatch.observer/filing/0000950170-25-012846.json
- Plain text: https://secwatch.observer/filing/0000950170-25-012846.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.